Norpramin

Insomnia, Bulimia Nervosa, Panic Disorder + 7 more

Treatment

1 FDA approval

20 Active Studies for Norpramin

What is Norpramin

Desipramine

The Generic name of this drug

Treatment Summary

Desipramine hydrochloride is a medication used to treat depression. It is a type of tricyclic antidepressant and works by blocking the reuptake of serotonin and norepinephrine, two neurotransmitters involved in mood regulation. Desipramine can also be used to address symptoms of neuropathic pain, agitation, and insomnia. Common side effects include sedation, blurred vision, dry mouth, constipation, and urinary retention. Desipramine has less anticholinergic and sedative side effects than other tricyclic antidepressants.

Norpramin

is the brand name

image of different drug pills on a surface

Norpramin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Norpramin

Desipramine

1964

122

Approved as Treatment by the FDA

Desipramine, also called Norpramin, is approved by the FDA for 1 uses including Depression .

Depression

Effectiveness

How Norpramin Affects Patients

Desipramine is a type of antidepressant drug that works by blocking the reabsorption of certain chemicals in the brain, such as noradrenaline and serotonin. It is more effective at blocking the reabsorption of noradrenaline compared to other antidepressants. After taking desipramine for a few weeks, it can increase the transmission of serotonin. It usually takes 2-4 weeks to notice the effects of desipramine, but people with more severe depression may see results faster.

How Norpramin works in the body

Desipramine is a medicine used to treat depression. It works by blocking the reuptake of two neurotransmitters, norepinephrine and serotonin. This means that the brain cells can keep more of these chemicals, which can help improve mood. Desipramine also affects some of the receptors that respond to these neurotransmitters, making them more sensitive. This can further increase the effect of the medication. Desipramine also has a small effect on certain parts of the brain that regulate muscle movement, which can cause some side effects.

When to interrupt dosage

The suggested amount of Norpramin is contingent upon the identified condition, including Irritable Bowel Syndrome (IBS), Neuropathic Pain and Chronic Pain. Dosage also depends on the mode of administration, outlined in the table below.

Condition

Dosage

Administration

Insomnia

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Irritable Bowel Syndrome

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Bulimia Nervosa

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Panic Disorder

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Depression

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Diabetic Neuropathy

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Neuralgia, Postherpetic

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Neuropathic Pain

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Anorexia Nervosa

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Chronic Pain

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Warnings

Norpramin has five contraindications and should not be administered while encountering the conditions found in the following table.

Norpramin Contraindications

Condition

Risk Level

Notes

Myocardial Infarction

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Norpramin.

Common Norpramin Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Desipramine.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Desipramine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Desipramine is combined with Aclidinium.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Desipramine.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Desipramine.

Norpramin Toxicity & Overdose Risk

The toxic dose of desipramine for male mice is 290 mg/kg and for female rats is 320 mg/kg. Taking desipramine can cause sedation and low blood pressure due to its effects on the histamine and alpha-1 receptors. Other side effects may include blurred vision, dry mouth, constipation, urine retention, high or low blood pressure, rapid heartbeat, changes in ECG, heart failure, confusion, impaired memory, manic episodes, nausea, vomiting, abdominal pain, diarrhea, anxiety, insomnia, nervousness, headache, and fatigue.

image of a doctor in a lab doing drug, clinical research

Norpramin Novel Uses: Which Conditions Have a Clinical Trial Featuring Norpramin?

791 active studies are investigating the potential of Norpramin to alleviate Anorexia Nervosa, Irritable Bowel Syndrome (IBS) and Depression.

Condition

Clinical Trials

Trial Phases

Diabetic Neuropathy

5 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Irritable Bowel Syndrome

5 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1

Panic Disorder

13 Actively Recruiting

Not Applicable

Anorexia Nervosa

0 Actively Recruiting

Insomnia

0 Actively Recruiting

Chronic Pain

0 Actively Recruiting

Neuropathic Pain

4 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Bulimia Nervosa

0 Actively Recruiting

Depression

305 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Neuralgia, Postherpetic

0 Actively Recruiting

Norpramin Reviews: What are patients saying about Norpramin?

5

Patient Review

9/9/2012

Norpramin for Depression

I've been taking this for over 20 years, and it's helped me a lot. I was originally diagnosed with Epstein Barr and depression, but this medication has worked well for me. About twice a year I go through a brief period of mild depression, but overall this drug is effective. I tried the generic version to save money, but it wasn't as effective. A few years ago I tried a newer drug on my doctor's recommendation, but I had a bad experience so I went back to Norpramin. The old saying is true: "If it works, don't fix it."

5

Patient Review

4/10/2009

Norpramin for Depression

I take 25 mg of this drug every night to help with my Prozac. I notice that I sleep better and feel more rested the next day. It's been working well for me and, since it's a generic, the cost isn't bad either.

5

Patient Review

9/26/2009

Norpramin for Depression

I've been taking this treatment for about ten years. I struggled with depression before starting it and it's worked so well that I'll probably take it for the rest of my life.

5

Patient Review

9/18/2010

Norpramin for Depression

Out of all the anti-depressants available, this tri-cyclic worked the best for me...It broke through the depression along with Pamalor......I am very thankful for this...

4.7

Patient Review

6/13/2012

Norpramin for Neuropathic Pain

Norpramin was highly effective for me in treating the burning sensation I had in my legs for five years. Within a week, the pain was gone and it never came back after six months of being off the medication. The only downside is that it affected my ejaculation.

4.3

Patient Review

8/18/2010

Norpramin for Depression

I recently started taking 100mg of this medication at bedtime, but have experienced significant constipation as a result. I'm going to speak to my doctor about it and see if there's anything that can be done.

4.3

Patient Review

7/29/2011

Norpramin for Depression

This medication has been really effective for me, better than any other depression med I've tried. The only downside is that I sweat a lot more than usual. It's not ideal, but it's worth it to me since this is the only thing that's helped so far.

4

Patient Review

7/8/2010

Norpramin for Depression

I saw no results from the generic version of this drug, but as soon as I switched to the brand name Norpramin, I started seeing improvements within a couple months. I've been taking it for preventative measures for over a decade now.

3.3

Patient Review

6/13/2010

Norpramin for Neuropathic Pain

I do feel some relief from this medication, but it is not as strong as I would like.

3

Patient Review

5/1/2013

Norpramin for Depression

I had to stop taking this medication because it caused severe constipation that woke me up at night. I'm glad it relieved my depression, but the other side effects weren't worth it.

2.7

Patient Review

8/26/2015

Norpramin for Depression

I was given desipramine to try to reduce acute depression. Only after 2 weeks did I start to improve; however, when I tried to reduce the dosage, I experienced severe migraine headaches which totally wiped me out. When I restarted it, the headaches/flu-like symptoms disappeared. Avoid this drug unless you're prepared to feel physically ill; I switched to Prozac, which was quite good.

2

Patient Review

8/2/2010

Norpramin for Neuropathic Pain

I was on this medication for approximately a year before my doctor increased the dosage. Unfortunately, this led to sudden cardiac death; however, I'm grateful that my wife was in the room at the time and knew CPR. Otherwise, I would not be here today.

1.7

Patient Review

4/13/2022

Norpramin for Attention Deficit Disorder with Hyperactivity

As a child in the '90s, I took Norpramin and it would cause me to black out when doing something repetitive—like riding my bike to 7-11. I even had cars honk at me while I was blacked out. Once, while riding my dirt bike down a country road, I blacked out and ran headfirst into a mailbox. If I hadn't been wearing a helmet, I would have died. So yeah, not great for kids.

1.7

Patient Review

8/14/2009

Norpramin for Depression

I experienced nearly fatal side effects from this treatment.

1

Patient Review

4/10/2014

Norpramin for Depression

I took too many of these at once and then walked out into the street. I was hit by a car as a result. Life has been hell ever since, both figuratively and literally.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about norpramin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Norpramin prescribed for?

"This medication may have positive effects on your mood, sleep, appetite, and energy level. It may also help you take more interest in daily activities. The medication belongs to a class of drugs known as tricyclic antidepressants. It works by restoring the balance of a certain neurotransmitter (norepinephrine) in the brain."

Answered by AI

Does desipramine cause weight gain?

"Do tricyclic antidepressants like desipramine cause weight gain? Yes, they can. However, some people have lost weight while taking this medication. Talk to your provider if your weight has changed a lot while taking desipramine.Jan 12, 2022"

Answered by AI

Is Norpramin still available?

"Yes, the generic version of Norpramin is called desipramine and is available for purchase."

Answered by AI

What are the side effects of desipramine?

"Side effects may include nausea, drowsiness, weakness or tiredness, nightmares, dry mouth, skin more sensitive to sunlight than usual, changes in appetite or weight, and constipation."

Answered by AI

Clinical Trials for Norpramin

Image of People Science in Los Angeles, United States.

Digestive Enzyme Blend for Abdominal Bloating

18+
All Sexes
Los Angeles, CA

This study is a randomized, double-blind, placebo-controlled, within-individual crossover trial designed to assess the impact of regular use of a consumer-grade FODMAP-targeting digestive enzyme blend (FODZYME®) on gastrointestinal symptoms in adults with self-reported bloating.1 The study's rationale is based on the fact that fermentable carbohydrates (FODMAPs) are often poorly absorbed and can trigger symptoms like bloating and abdominal pain. While a Low FODMAP Diet (LFD) is clinically validated for symptom relief, it is restrictive. The enzyme blend is intended to offer a more flexible, enzyme-based solution by targeting and breaking down FODMAPs, such as fructan, GOS, and lactose, before they ferment in the colon. The primary objective is to evaluate the product's impact on bloating symptoms, measured by the mean PROMIS scale Gastrointestinal Gas and Bloating score. Secondary and exploratory objectives include assessing the impact on overall gastrointestinal symptom severity (IBS-SSS), abdominal pain (PROMIS Belly Pain score), food-related quality of life (FR-QoL-29), and anxiety (GAD-7 scores). The study also aims to evaluate these effects across various Irritable Bowel Syndrome (IBS) subgroups (IBS-C, IBS-D, IBS-M). The trial is a consumer-driven, decentralized research study utilizing validated patient-reported outcome measures that can be completed in a home setting.

Recruiting
Paid Trial

People Science

Ashley Mateus, Ph.D.

People Science, Inc.

Image of Washington University School of Medicine in St Louis, United States.

Psilocybin-Assisted Therapy for Depression

18+
All Sexes
St Louis, MO

Depression is the leading cause of disability worldwide, affecting an estimated 300 million people. Despite available treatments, response rates remain modest, and treatment resistance is common. Novel treatments are needed that act rapidly, produce lasting effects and work differently than existing antidepressants. In clinical trials, psilocybin has shown promise as a treatment for depression due to its rapid onset of antidepressant effects and sustained benefits. This study will use MRI scanning of the brain and other biological measures (biomarkers) to investigate how psilocybin affects brain activity and psychological flexibility before, during, and after receiving psilocybin in participants with depressive symptoms.

Phase 2
Waitlist Available

Washington University School of Medicine

Image of University of California, Los Angeles in Los Angeles, United States.

Digital Therapy for Postpartum Depression

18+
Female
Los Angeles, CA

The purpose of this study is to determine if the addition of digital sensing data collected from phones and watches during the early stages of perinatal depression (PND) treatment can better predict treatment outcomes than using self-reported symptoms alone.STAND for PND: The UCLA Depression Grand Challenge (DGC) has previously developed a technology-assisted, scalable therapy system called STAND (Screening and Treatment for ANxiety and Depression) for perinatal depression (PND) and has demonstrated in an initial randomized clinical trial that this treatment intervention to be as effective as psychiatrist delivered care for PND. In this study, the investigators will administer STAND for PND for up to 12 weeks as part of study participation. There will be no comparison between our treatment intervention and a treatment as usual condition, as this is not a trial of efficacy. In the STAND for PND treatment model, women with moderate symptoms will be routed to coach-guided, digital cognitive behavioral therapy (CBT) tailored to PND, which has been demonstrated to be an effective treatment approach for PND. Women with severe depression or suicidality will be routed to clinician delivered CBT, with pharmacotherapy as needed, with both CBT and pharmacotherapy demonstrated to be effective treatment approaches for PND. Symptoms will be regularly monitored throughout the intervention period. Digital Sensing in Depression: The DGC also has substantial experience in large-scale longitudinal digital sensing studies, and experience identifying associations between self-report or clinical ratings of depressive symptoms and digital sensing features, including in pregnant and postpartum women. Digital Sensing in a STAND for PND study: In our previous STAND for PND study, the investigators did not include digital sensing. In this next phase of our research program, the investigators will collect digital sensing data from phones and watches during the first four weeks of study participation. The investigators will enroll up to 250 women during their last trimester or who are in the postpartum period to participate in the 12-week study, which includes treatment provided through the STAND for PND program of care and during which the investigators will obtain 4-weeks of digital sensing data.The investigators will be testing whether behaviors measures through digital sensing (i.e., digital features) in combination with self-reported depression symptoms will better predict treatment outcomes than the self-reported depression symptoms alone. The investigators are testing the hypothesis that prospective longitudinal assessments using digital devices will enhance our ability to predict outcomes of STAND-PND.This project is part of a larger program of research that aims to improve clinical decision-making for PND by establishing a clinical care model for PND that fully integrates digital sensing with digital therapy. An additional objective of this program of research is to target low-income mothers from populations that have had limited access to mental healthcare, given that this population is particularly vulnerable to the impact of PND.

Waitlist Available
Has No Placebo

University of California, Los Angeles

Nelson Freimer, MD

Image of Imperial Valley College in Imperial, United States.

Cognitive Behavioral Therapy for Mental Health

18+
All Sexes
Imperial, CA

The goal of this study is to understand why certain treatments help people reduce repetitive negative thinking (RNT), which is common in many mental health problems. We want to: 1. Figure out what actually causes repetitive negative thinking to decrease when people use cognitive-behavioral therapy (CBT). 2. Find out which parts of RNT-focused CBT are the most important - the parts that truly make a difference in reducing RNT. The main result we will look at is how much a person's repetitive negative thought patterns change from the start of the study to the end of treatment (16 weeks). We will measure this using the Perseverative Thinking Questionnaire at baseline and week 16.

Waitlist Available
Has No Placebo

Imperial Valley College

Have you considered Norpramin clinical trials?

We made a collection of clinical trials featuring Norpramin, we think they might fit your search criteria.
Go to Trials
Image of The Korean Association of West Florida in Tampa, United States.

Mobile App Mindfulness for Mental Health

18+
All Sexes
Tampa, FL

The goal of this clinical trial (single-arm pilot trial) is to learn whether a mobile application-based mindfulness intervention can improve mental health outcomes in older Korean immigrants aged 60 years and older. The main questions it aims to answer are whether the 8-week mobile app-based mindfulness intervention is feasible and acceptable, as indicated by recruitment, retention, and adherence rates, and whether participation in the intervention leads to improvements in positive psychological well-being (e.g., positive affect, optimism, life engagement, and mindfulness) and reductions in adverse mental health outcomes (e.g., anxiety, depressive symptoms, and perceived stress). Participants will complete baseline and post-intervention assessments, receive training on how to use the mobile mindfulness application, engage with the app for approximately 8 weeks (recommended 10-15 minutes per day), and participate in weekly check-ins to support engagement and address any challenges encountered during the intervention.

Waitlist Available
Has No Placebo

The Korean Association of West Florida (+1 Sites)

Soonhyung Kwon

Image of Brown University in Providence, United States.

Mindfulness-Based Intervention for Mental Health

18 - 24
All Sexes
Providence, RI

The goal of this clinical trial (single-arm feasibility study) is to examine the feasibility, acceptability, and preliminary efficacy of a mindfulness-based, app-delivered intervention to address mental health and emotion regulation challenges in young adults with early life adversities (ELAs). The main questions it aims to answer is: \- Will young adults find the Growth, Empowerment, and Mindfulness (GEM) intervention to be both feasible and acceptable, as demonstrated by participants' engagement and quantitative/qualitative feedback? Additionally, it aims to answer: * Will GEM intervention demonstrate preliminary efficacy in improving outcome measures including depression, anxiety? * Are improvements in mindfulness and sleep, as well as reductions in rumination, mechanisms of action underlying the improvements in psychological and behavioral outcomes of the intervention? Participants will be asked to: * participate in GEM, which integrates app-based intervention content, formal and informal mindfulness practices, weekly Zoom group sessions, and ecological momentary intervention (EMI) delivery * complete baseline, post-intervention, and 3-month follow-up assessments * complete weekly assessments and daily ecological momentary assessments (EMAs) during the intervention delivery * wear Fitbit for researchers to collect sleep-related data

Waitlist Available
Has No Placebo

Brown University

Shufang Sun, PhD

Image of Michael E. DeBakey VA Medical Center, Houston, TX in Houston, United States.

Behavioral Activation-Guided Self-Help for Depression

18+
All Sexes
Houston, TX

Symptoms of depression are highly prevalent among Veterans. However, fewer than 30% of individuals with these symptoms receive any psychotherapy in the Veterans Health Administration (VHA). This is due to many factors, which may include provider availability and patient preferences. Guided self-help (GSH), which involves coaching sessions with patients who are following a fully developed self-help program, has the potential to increase access to care for these Veterans, particularly if implemented within a stepped care model of mental health treatment delivery and if delivered by a diverse set of providers. The VHA's primary care-mental health integration (PCMHI) service, which focuses on short courses of care for mild to moderate symptoms, may be an ideal place in which to deploy GSH. The current project seeks conduct a pilot randomized trial of a GSH program for depression adapted for PCMHI based on behavioral activation.

Waitlist Available
Has No Placebo

Michael E. DeBakey VA Medical Center, Houston, TX

Maribel Plasencia, BA MS PhD

Image of Vanderbilt University Medical Center in Nashville, United States.

Cognitive Training + tDCS for Depression

18+
All Sexes
Nashville, TN

The goal of this clinical trial is to learn if a combination of non-drug treatments works to benefit memory, thinking, and brain functioning in older individuals with recurrent depression. The non-drug approaches the investigators are studying include transcranial direct current stimulation (tDCS) and computerized cognitive training. tDCS uses small currents of electricity on the forehead to potentially stimulate your brain's ability to process and learn. Computerized cognitive training uses tablet games to improve memory and thinking. In this study, two different cognitive training programs are being investigated, both of which are stimulating and designed to engage brain activity. One that is believed to be a specific treatment for depression, while the other provides extra stimulation for the brain that is non-specific. Two different tDCS parameters - active stimulation and sham (or placebo) stimulation - are also being investigated. Participants will be randomized to one of three study groups: 1. Depression cognitive training treatment with active brain stimulation 2. Depression cognitive training treatment with sham brain stimulation 3. Non-specific cognitive training treatment with sham brain stimulation The main questions this clinical trial aims to answer are: * Does "depression cognitive training treatment with active brain stimulation" benefit thinking and memory more so than the other treatments? * Does "depression cognitive training treatment with active brain stimulation" benefit brain functioning more so than the other treatments? Participants will: * Complete several baseline and post-intervention visits at the research center for checkups and tests over the course of 3-4 months. * Visit the research center daily for 4 weeks to complete their assigned treatment.

Waitlist Available
Has No Placebo

Vanderbilt University Medical Center

Have you considered Norpramin clinical trials?

We made a collection of clinical trials featuring Norpramin, we think they might fit your search criteria.
Go to Trials
Image of UF World Equestrian Center in Ocala, United States.

ONE-D TMS + D-Cycloserine for Depression and Concussion

18 - 65
Female
Ocala, FL

Concussion and depression have long been recognized to be intertwined pathologies.1-3 Although female athletes are more likely to suffer from mental health symptoms than males athletes following a concussion,2 research in this area has been largely biased toward males.4 Recently functional MRI (fMRI) studies5 in concussed athletes have established that there are patterns of local alterations in neural connectivity in the frontal cortex that demonstrate anatomic congruency with transcranial magnetic stimulation (TMS) studies that mapped alternations in neural connectivity to functional and somatic symptoms.6 Thus, there is potential that TMS treatment could decrease both symptom profiles, revolutionizing comorbid treatment options. Possible Benefits: Previous studies have showed a 70% remission rate for depression symptoms. It is possible that participants could have improvement in depressive or concussive symptoms after the ONE-D TMS treatment.

Phase 2 & 3
Waitlist Available

UF World Equestrian Center

Sara Gould, MD

Image of CVT in Centennial, United States.

Treatment for Chronic Pain

18 - 70
All Sexes
Centennial, CO

The goal of this hybrid implementation-effectiveness study is to learn about the effectiveness and appropriateness of "Trauma-Informed and Culturally-Responsive Integrated Massage Therapy" (TCI-Massage) for torture and war trauma survivors. The study aims are: • Examine the uptake of TCI-Massage within CVT by assessing key implementation science outcomes of acceptability and appropriateness among refugees and asylum seekers from diverse cultural backgrounds. • Examine the integration of massage therapy into the current psychosocial care model used at CVT. • Examine the effectiveness of TCI-Massage for torture and war trauma survivors to reduce distress (mental health symptoms, chronic pain, and HRV) and improve coping (interoceptive awareness and social functioning). Treatment group participants will participate in psychosocial care services + TCI-Massage, which the control group will only participate in psychosocial care services

Waitlist Available
Has No Placebo

CVT

Have you considered Norpramin clinical trials?

We made a collection of clinical trials featuring Norpramin, we think they might fit your search criteria.
Go to Trials